<DOC>
	<DOC>NCT01802996</DOC>
	<brief_summary>This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.</brief_summary>
	<brief_title>Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury</brief_title>
	<detailed_description>Total subjects: 2040, experimental group of 1360 patients, control group of 680 patients. According to the study subjects receiving antineoplastic chemotherapy, subjects are stratified randomize.</detailed_description>
	<mesh_term>Wounds and Injuries</mesh_term>
	<criteria>1. Male or female aged 1875 years; 2. Patients with malignant tumor accord with chemotherapy indication, candidate to a chemotherapy treatment, disease is not restricted; 3. Accorded with the following chemotherapy plan: included cisplatinum, ≥60mg/m2/course; included oxaliplatin, ≥85mg/m2/course; included cyclophosphamide, ≥600mg/m2/course; included gemcitabine, ≥60mg/m2/course; 4. ECOG≤2; 5. Estimates survival time≥3 months; 6. TBIL≤1.0×ULN, ALT、AST≤1.0×ULN; blood examination, uronoscopy, stool examination, renal function tests and electrocardiogram are normal; 7. Patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks). 1. Patients with partial liver radiotherapy; 2. Hepatitis B or C virus replication in the state, the patient will need antiviral therapy; 3. Patients have serious heart diseases, liver kidney diseases, or metabolism function disorder; 4. Patients combined with cellular immune therapy; 5. Within 2 weeks of application or currently possible applications of drugs(polyene phosphatidylcholine, reduced glutathione, tiopronin and other hepatoprotective and choleretic drugs), interference with the study; 6. Pregnancy, or patients during breast feeding; 7. Patients have known hypersensitivity to Glycyrrhizin; 8. Patients are participating, or have participated in other Clinical studies of new drugs within 4 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>